Endocrine Abstracts

Background: General Medical Council (GMC) guidance describes an intimate examination as one that may be embarrassing for the patient, for example, breast or genitalia examination. Documentation of consent and use of a trained impartial observer (chaperone) is recommended for intimate examinations. Pubertal staging is often necessitated for assessment of growth and puberty. We assessed current practice in pubertal staging by paediatricians and paediatric endocrinology nurse spe...

Background: Cardiometabolic (CM) risk is linked to being small for gestational age (SGA, birthweight <-2SDS). Suboptimal fetal growth alone may be linked with greater CM risk without resulting in SGA. Therefore, we focused on CM risk in children born following pregnancies at higher risk for growth restriction, irrespective of birthweight.Aims: 1. To identify associations between fetal and childhood weight trajectories and CM risk markers. 2. To defin...

Central precocious puberty (CPP) is a common and well-recognised condition characterised by premature activation of the hypothalamic-pituitary-gonadal axis, with consequent potential adverse health and psychosocial outcomes. Standard management of CPP is with periodic injections of gonadotropin-releasing hormone analogue therapy. Decapeptyl SR (Triptorelin pamoate) has for several years been available as a long-acting (12-weekly, 11.25 mg) preparation, but more recently is ava...

Background: The highest rates of childhood obesity are among children from lower socioeconomic groups. Tier 3 weight management services for children currently rely on an MDT approach that is focused on the management of complications associated with excessive weight, but the resources are generally limited. Evidence suggests that the input in the community is key to empower children, young people, and their families to make healthy lifestyle changes, although the availability...

Background: 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is characterised by cortisol deficiency, androgen excess, varying degrees of virilisation and salt-wasting. CAH management involves replacement therapy with hydrocortisone, and, often, fludrocortisone. High levels of androgens cause the advancement of bone age (BA) with the potential to increase bone mineralisation. Hydrocortisone therapy on the contrary can contribute to reducing bone mineralisation. P...